A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice

Cancer Letters

Volumn 295, Issue 1, 2010, Pages 124-133

  Zhong, Genshen ^a   Zhang, Shenghua ^a   Li, Yi ^a   Liu, Xiujun ^a   Gao, Ruijuan ^a   Miao, Qingfang ^a   Zhen, Yongsu ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Antibody; Gelatinases; Lidamycin; Tumor targeting

Indexed keywords

GELATINASE; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG CARCINOMA; MICROVASCULATURE; MITOSIS INDEX; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

AMINOGLYCOSIDES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPROTEINS; CELL PROLIFERATION; ENEDIYNES; GELATINASES; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICROVESSELS; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 77953546364     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.02.020     Document Type: Article

References (39)

1. Jain M., Kamal N., Bastra S.K. Engineering antibodies for clinical applications. Trends Biotechnol. 2007, 25:307-316.
2. Potala S., Sahoo S.K., Verma R.S. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins. Drug Discov. Today 2008, 13:807-815.
3. Sharkey R.M., Goldenberg D.M. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J. Clin. 2006, 56:226-243.
4. Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 2005, 23:1137-1146.
5. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 2001, 7:1490-1496.
6. Shao R.G., Zhen Y.S. Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology. Anticancer Agents Med. Chem. 2008, 8:121-131.
7. Shao R.G., Zhen Y.S. Relationship between the molecular composition of C1027, a new macromolecular antibiotic with enediyne chromophore, and its antitumor activity. Acta Pharmcol. Sin. 1995, 30:336-342.
8. Shao R.G. Pharmacology and therapeutic applications of enediyne antitumor antibiotics. Curr. Mol. Pharmacol. 2008, 1:50-60.
9. Beerman T.A., Gawron L.S., Shin S., Shen B., Mchugh M.M. C-1027, a radiomimetic enediyne anticancer drug, preferentially targets hypoxic cells. Cancer Res. 2009, 69:593-598.
10. David H.S. Characterization of novel multifunctional proteins involved in assembly of the enediyne natural products C-1027 and calicheamicin furthers the potential of combinatorial biosynthesis. Nat. Biotechnol. 2002, 20:984-985.
11. Bjorklund M., Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim. Biophys. Acta 2005, 1755:37-69.
12. Kallakury B.V.S., Karikehalli S., Haholu A., Sheehan C.E., Azumi N., Ross J.S. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin. Cancer. Res. 2001, 7:3113-3119.
13. Cho Y.B., Lee W.Y., Song S.Y., Shin H.J., Yun S.H., Chun H.K. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum. Pathol. 2007, 38:1603-1610.
14. Belotti D., Paganoni P., Manenti L., Garofalo A., Marchini S., Taraboletti G., et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003, 63:5224-5229.
15. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13:193-205.
16. Li L., Huang Y.H., Li Y., Wang F.Q., Shang B.Y., Zhen Y.S. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma. World J. Gastroenterol. 2005, 11:4478-4483.
17. Wang F.Q., Shang B.Y., Zhen Y.S. Antitumor effects of the immunoconjugates composed of lidamycin and monoclonal antibody 3G11. Acta Pharmacol. Sin. 2003, 38:515-519.
18. Holliger P., Hudson P. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
19. Wu A.M., Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008, 14:191-197.
20. Li L., Yazaki P.J., Anderson A.L., Crow D., Colcher D., Wu A.M., et al. Improved biodistribution and radioimmunoimaging with poly(ethyleneglycol)-DOTA-conjugated anti-CEA diabody. Bioconjugate Chem. 2006, 17:68-76.
21. Zhang Y.J., Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin. Cancer Res. 2008, 14:7981-7986.
22. Zhu W., Zheng J., Fang W. Isolation and characterization of human lung cancer cell subline with different metastatic potential. Zhonghua Bing Li Xue Za Zhi 1995, 24:136-138.
23. Yang W., Luo D., Wang S., Chen R., Liu Y., Zhu T., et al. TMTPI, a novel tumor-homing peptide specifically targeting metastasis. Clin. Cancer Res. 2008, 14:5494-5502.
24. Zhang W., Chen Y., Wei H., Zheng C., Sun R., Zhang J., et al. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22 small interfering RNA on human lung cancer xenografts. Clin. Cancer Res. 2008, 14:6432-6439.
25. Miao Q.F., Liu X.J., Shang B.Y., Ouyang Z.G., Zhen Y.S. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity. Anti-Cancer Drugs 2007, 18:127-137.
26. Tsumoto K., Shinoki K., Kondo H., Uchikawa M., Juji T., Kumagai I. Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent-application to a human single-chain Fv fragment. J. Immunol. Methods 1998, 219:119-129.
27. Williams J.I., Weitman S., Gonzalez C.M., Jundt C.H., Marty J., Stringer S.D., et al. Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin. Cancer Res. 2001, 7:724-733.
28. Weitman S., Marty J., Jolivet J., Locas C., Von Hoff D.D. The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin. Cancer Res. 2000, 6:1574-1578.
29. Guha S., Eibl G., Kisfalvi K., Fan R.S., Burdick M., Reber H., et al. Broad-spectrumGproteincoupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res. 2005, 65:2738-2745.
30. Gao J., Kou G., Wang H., Chen H., Li B., Lu Y., et al. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity. Breast Cancer Res. Treat. 2009, 115:29-41.
31. Tanaka T., Fukuda-Ishisaka S., Hirama M., Otani T. Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore. J. Mol. Biol. 2001, 309:267-283.
32. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
33. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001, 411:375-379.
34. Melani C., Sangaletti S., Barazzetta F.M., Werb Z., Colombo M.P. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007, 67:11438-11446.
35. Dai Y., Jia B., Wang F., Du J., Shang B.Y., Zhen Y.S. Immunoscintigraphy of anti-type IV collagenase monoclonal antibody in nude mice bearing human lung cancer xenograft. Ai Zheng 2003, 22:1243-1248.
36. Inoue M., Usuki T., Lee N., Hirama M., Tanaka T., Hosoi F., et al. Antitumor enediyne chromoprotein C-1027: mechanistic investigation of the chromophore-mediated self-decomposition pathway. J. Am. Chem. Soc. 2006, 128:7896-7903.
37. Jang S.H., Wientjes M.G., Lu D., Au J.L. Drug delivery and transport to solid tumors. Pharm. Res. 2003, 20:1337-1350.
38. Arribas J., Borroto A. Protein ectodomain shedding. Chem. Rev. 2002, 102:4627-4638.
39. Dello Sbarba P., Rovida E. Transmodulation of cell surface regulatory molecules via ectodomain shedding. Biol. Chem. 2002, 383:69-83.